# Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

> **NCT05263206** · PHASE3 · RECRUITING · sponsor: **Sanofi** · enrollment: 284 (estimated)

## Conditions studied

- Pruritus

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo
- **DRUG:** Fexofenadine (loratadine if not available)

## Key facts

- **NCT ID:** NCT05263206
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-15
- **Primary completion:** 2027-06-02
- **Final completion:** 2027-08-25
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263206, "Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05263206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*